The Drugs.com Monthly Update Podcast

Drugs.com
  • 0.0 (0)
  • Medicine

The "Monthly Update" Podcast from Drugs.com delivers monthly roundups of new drug approvals, updated indications, safety alerts, and the latest healthcare news.

  1. Jul 3

    Drugs.com - Monthly Update June 2026

    This month, we're exploring advances across multiple therapeutic areas. We cover Lumvoa for thyroid eye disease, Utebzi for complicated urinary tract infections, and Tregzi for blood cancers. Lumvoa (veligrotug-vvze): Approved for thyroid eye disease, Lumvoa is an IGF-1R inhibitor that offers significant improvements in TED symptoms, with notable early effectiveness.Utebzi (tebipenem pivoxil): The first oral carbapenem approved in the U.S., providing a new option for treating complicated urinary tract infections, demonstrating efficacy comparable to intravenous options.Tregzi (Orca-T or allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq): A precision-engineered cell therapy for use in donor stem cell transplantation, to help rebuild the blood and immune system, and to improve chronic graft-versus-host disease (GVHD)-free survival, in adults with blood cancers (hematological malignancies).Chapters: (00:21) - Intro (00:41) - Lumvoa (01:42) - Utebzi (02:42) - Tregzi (03:21) - Outro Follow Drugs.com:X, Facebook, YouTubeSign up to our newslettersDownload the app

    Drugs.com - Monthly Update June 2026

  2. Jun 3

    Drugs.com - Monthly Update May 2026

    In this May 2026 Monthly Update edition, we cover several new FDA approvals and a major prescription-to-OTC switch expanding therapeutic options. Veppanu (vepdegestrant): The first PROTAC (PROteolysis TArgeting Chimera) therapy to be approved for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer based on strong progression-free survival clinical data.Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate): A triple-combination inhalation aerosol approved for the long-term maintenance treatment of adult asthma.Xocova (ensitrelvir): The first oral antiviral tablet indicated for post-exposure prophylaxis (PEP) to prevent COVID-19 following exposure.Baxfendy (baxdrostat): A first-in-class oral aldosterone synthase inhibitor approved to treat uncontrolled hypertension in combination with other agents.Differin Epiduo Acne Gel (adapalene/benzoyl peroxide): A prescription combination acne treatment newly approved for over-the-counter (OTC) use.Zaynich (cefepime/zidebactam): An intravenous antibiotic approved for adults suffering from complicated urinary tract infections and pyelonephritis.Immgolis (golimumab-sldi): The first interchangeable biosimilar to Simponi approved for adult rheumatoid arthritis and ulcerative colitis.Chapters: (00:20) - Intro (00:58) - Veppanu (01:58) - Trimbow (03:13) - Xocova (04:28) - Zaynich (05:31) - Baxfendy (06:28) - Differin Epiduo Acne Gel (07:28) - Immgolis (08:06) - Outro Follow Drugs.com:X, Facebook, YouTubeSign up to our newslettersDownload the app

    Drugs.com - Monthly Update May 2026

  3. May 2

    Drugs.com - Monthly Update April 2026

    In this April 2026 Monthly Update edition, we highlight several FDA approvals that introduce first-of-their-kind therapies and improve access to existing treatments. Foundayo (orforglipron): A first-of-its-kind small-molecule oral GLP-1 receptor agonist for chronic weight management without strict food or water requirements.Otarmeni (lunsotogene parvec-cwha): An innovative gene therapy for pediatric and adult patients with OTOF-related genetic hearing loss.Idvynso (doravirine and islatravir): A new once-daily, two-drug single-tablet regimen for adults with HIV-1 who are virologically suppressed.Langlara (insulin glargine-aldy): A interchangeable biosimilar to Lantus for the treatment of type 1 and type 2 diabetes.Chapters: (00:21) - Intro (01:05) - Foundayo (01:59) - Otarmeni (02:55) - Idvynso (03:50) - Langlara (04:42) - Outro Follow Drugs.com:X, Facebook, YouTubeSign up to our newslettersDownload the app

    Drugs.com - Monthly Update April 2026

  4. Apr 2

    Drugs.com - Monthly Update March 2026

    In this March 2026 edition of Drugs.com Monthly Update Podcast, learn about the FDA's latest approvals, including Wegovy HD for obesity, Icotyde for plaque psoriasis, Sotyktu for psoriatic arthritis, and Awiqli for type 2 diabetes.  Wegovy HD (semaglutide): A new high-dose option for adults managing obesity, showing significant weight loss in clinical trials. Icotyde (icotrokinra): The first oral IL-23 blocker approved to treat moderate-to-severe plaque psoriasis, providing a new oral treatment choice. Sotyktu (deucravacitinib): An oral TYK2 inhibitor now approved for treating active psoriatic arthritis, addressing inflammation with a convenient dosing regimen. Awiqli (insulin isodec): The first once-weekly basal insulin for adults with type 2 diabetes. Chapters: (00:21) - Intro (01:00) - Wegovy HD (02:10) - Icotyde (03:12) - Sotyktu (03:53) - Awiqli (04:32) - Outro Follow Drugs.com:X, Facebook, YoutubeSign up to our newslettersDownload the app

    Drugs.com - Monthly Update March 2026

  5. Mar 2

    Drugs.com - Monthly Update February 2026

    In this February 2026 edition of Drugs.com Monthly Update Podcast, learn about new options in weight management, type 2 diabetes, and lung cancer. Discover Eli Lilly's Zepbound KwikPen for simplified dosing in obesity management, the upcoming launch of the oral Ozempic pill for diabetes by Novo Nordisk, IBSA Pharma’s oral film formulation of sildenafil for erectile dysfunction called Vybrique, and the monthly Rybrevant Faspro injection for advanced NSCLC. Zepbound KwikPen (tirzepatide): A new multidose Zepbound pen supplying 4 fixed weekly doses in one pen Ozempic pill (semaglutide): Discover the upcoming once-daily oral option for adults with type 2 diabetes to manage blood sugar and cardiovascular risks.Rybrevant Faspro (amivantamab and hyaluronidase-lpuj): Explore the benefits of a simplified, monthly injectable regimen for EGFR-mutated NSCLC.Dupixent (dupilumab): The first approved therapy for allergic fungal rhinosinusitis, reducing the need for systemic steroids.Vybrique (sildenafil): A new oral film formulation of sildenafil for erectile dysfunction.Calquence + Venetoclax (acalabrutinib combination): This new all-oral regimen provides a targeted therapy for CLL, improving patient outcomes with a non-chemo approach.Chapters: (00:00) - Intro (00:20) - Overview Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    Drugs.com - Monthly Update February 2026

  6. Feb 2

    Drugs.com - Monthly Update January 2026

    In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin. Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.Zycubo (copper histidinate), the first treatment for Menkes disease in children.Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.Chapters (00:00) - Intro (00:21) - Overview (00:47) - Darzalex (02:13) - Yuvezzi (03:06) - Zycubo (03:50) - Nexplanon (04:35) - Afrezza (05:09) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    Drugs.com - Monthly Update January 2026

  7. Jan 1

    Drugs.com - Monthly Update December 2025

    This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up. Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials.Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity.Exdensur (depemokimab-ulaa), a new long-term, add-on treatment for severe eosinophilic asthma with twice-yearly injections.Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor whose approval has been extended to include chronic lymphocytic leukemia and small lymphocytic lymphoma.Lerochol (lerodalcibep-liga), a third-generation, PCSK9 inhibitor for high cholesterol self-administered via a monthly injection.Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy with extended approval to include relapsed or refractory marginal zone lymphoma.Chapters (00:00) - Intro (00:22) - Overview (00:34) - Wegovy (01:16) - Myqorzo (02:07) - Exdensur (02:56) - Jaypirca (03:31) - Lerochol (04:09) - Breyanzi (04:46) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    Drugs.com - Monthly Update December 2025

  8. 12/01/2025

    Drugs.com - Monthly Update November 2025

    In this episode, we explore key FDA approvals from November 2025, including treatments like Keytruda Qlex for bladder cancer, Epkinly for follicular lymphoma, and the long-acting Eylea HD for macular edema. Discover what these developments mean for patients and professionals alike. Keytruda (pembrolizumab), approved in combination with Padcev as neoadjuvant treatment for adults with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy, demonstrating a 60% reduction in event-free survival events.Epkinly (epcoritamab-bysp) plus rituximab and lenalidomide, approved for adults with relapsed or refractory follicular lymphoma, showing a 79% reduction in disease progression risk through T-cell engagement with malignant B-cells.Darzalex Faspro (daratumumab and hyaluronidase-fihj), now the first and only approved treatment for patients with high-risk smoldering multiple myeloma, significantly slowing disease progression.Eylea HD (aflibercept ophthalmic), approved for macular edema following retinal vein occlusion with extended up to every 8-week dosing after initial treatment, maintaining visual acuity with less frequent administration.Caplyta (lumateperone), newly approved as an add-on therapy for adults with major depressive disorder, enhancing outcomes when used alongside existing antidepressants.Chapters: (00:00) - Intro (00:37) - Discussion points (00:47) - Keytruda (01:20) - Epkinly (02:10) - Darzalex (02:47) - Eylea HD (03:14) - Caplyta (03:43) - Key takeaways (04:02) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app

    Drugs.com - Monthly Update November 2025
See All (13)

About

The "Monthly Update" Podcast from Drugs.com delivers monthly roundups of new drug approvals, updated indications, safety alerts, and the latest healthcare news.

Information